Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis

Neurol Neuroimmunol Neuroinflamm. 2020 Jun 10;7(5):e799. doi: 10.1212/NXI.0000000000000799. Print 2020 Sep.

¹ From Jesus College (J.B., S.R.L.S.), Cambridge University, UK; Department of Neurology (J.L.J., S.R.L.S.), Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; and Department of Neurology (S.R.L.S.), Peterborough City Hospital, North West Anglia NHS Foundation Trust, Peterborough, UK.
² From Jesus College (J.B., S.R.L.S.), Cambridge University, UK; Department of Neurology (J.L.J., S.R.L.S.), Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; and Department of Neurology (S.R.L.S.), Peterborough City Hospital, North West Anglia NHS Foundation Trust, Peterborough, UK. srls2@cam.ac.uk.

No abstract available

Publication types